15 January 2020

PainChek® secures Japanese patent, progressing global expansion

15th January 2020: Listed Australian company PainChek® (ASX:PCK) has been granted a patent in Japan for its smart phone pain assessment and monitoring technology.

The PainChek app automatically detects pain via artificial intelligence and facial recognition software. It effectively uses smartphone technology to give a voice to people who cannot verbalise their pain. The technology is currently being rolled out via residential aged care facilities in Australia following a $5M funding contribution from the Australian Federal Government.

According to PainChek CEO Philip Daffas, the patent in Japan is particularly significant given the size of the population and Japan's ageing demographic (See https://en.wikipedia.org/wiki/Demographics_of_Japan).

"Recent estimates suggest that at least one in four Japanese residents is aged 65 years or older. Japan has a big population – around 126 million - and the number of elderly people is set to grow significantly in the future. This patent is an important step in opening up significant commercial opportunities for PainChek, especially given the focus on quality aged care services in Japan," said Daffas.

PainChek is continuing to complete important international milestones as part of its global expansion plans.

The company also recently secured a patent in the USA for its pain assessment app. The USA patent will allow PainChek® to protect the intellectual property of its invention in the United States and provides a platform for growing the brand in other markets.

PainChek is also on track to obtain United States FDA DeNovo regulatory clearance. The DeNovo process provides a pathway to classify novel medical devices and will allow PainChek® to begin marketing the invention in the US.

PainChek secured its first United Kingdom order with the signing of a 1,000-bed annual license in 2019. It also completed the registration of its trademark in the USA and the European Union.

"All early indications are that the global demand for PainChek will be substantial. With regulatory clearance in a range of markets, international patents being secured, trademarks being granted and the company starting to secure sales in the UK, we feel uniquely positioned to leverage the full global value of our remarkable IP and all the hard work to this point," said Daffas.

This release is authorised by Philip Daffas, Managing Director & CEO.

ENDS

For further information please contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit
www.painchek.com

PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.

PainChek® domains of pain assessment that calculates pain severity score.